EUROPEAN ASSOCIATION OF HAEMOPHILIA AND ALLIED D..

18th Annual EAHAD Congress

 

4 - 7 February 2025 Milan
Close
N. Poster
Poster title
Applicant name
Status
  3-NUR Interim results from the Lived Experience of von Willebrand Disease (vWD 360) study Kate Khair Received Received
  3-PO APTT Mixing Studies-Pilot survey: Results and analysis from the UK NEQAS BC Haemophilia programmes 2024 Anna Williams Received Received
  4-PT Measurement properties of a core outcome set monitoring physical capability in people with haemophilia David Stephensen Received Received
  5-PO Ex vivo Comparison of Mim8 Combined with Activated Factor XI Versus Tissue Factor in Thrombin Generation Assays Kati Rehberg Received Received
  15-PO Diagnosis of assay discrepancy in mild haemophilia A using chromogenic FVIII:C with extended incubation time Annette Bowyer Received Received
  16-PO High-quality standardised ELISA to manage dose adjustments during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in the routine clinical setting: Test access model description Naveen Shridhar Received Received
  17-PO Lipoprotein (a) in hemophilia A and B patients Tuukka Helin Received Received
  18-PO Progress and Challenges in Hemophilia Management at BDTH-KASU Hemophilia Treatment Center, Kaduna Lgdogara Dr. Livingstone Gayus Dogara Received Received
  23-PO Pharmacokinetic evaluation of extended half-life versus standard half-life factor VIII: Real-life conditions Natalia duque Zapata Received Received
  24-PO D-dimers levels in patients with haemophilia A and B Brigitte Tardy Received Received
  25-PO Natural history of AAV5 neutralising antibodies in adults with haemophilia B during =6-month screening and lead-in to the HOPE-B trial with etranacogene dezaparvovec gene therapy Janeen Nuttall Received Received
  28-PO Role of Factor VIII in Promoting Endothelial Cell Function and Membrane Stability Gillian Patman Received Received
  29-PO Role of factor VIII in the regulation of endothelial cell function and extracellular matrix protein expression Gillian Patman Received Received
  30-PO Impact of variable recombinant factor VIII binding on platelet functions Gillian Patman Received Received
  31-PO Characterization of a F8-/-IgH-/- double knockout mouse model of hemophilia A for long-term exposure to factor VIII products Gillian Patman Received Received
  35-PO Efficacy and safety of concizumab prophylaxis in patients with haemophilia and inhibitors: Results from the Early Access Program in France Alexandre Butelet Received Received
  38-PO PedNet real world experience of emicizumab prophylaxis started in PUPs and MTPs with severe hemophilia A Marloes de Kovel Received Received
  41-PO Growing up with N9-GP: Safety and efficacy of prophylaxis for up to eleven years in children with haemophilia B Sarah Christopher Received Received
  42-PO Evaluation of the risk factor for developing cardiovascular diseases in adult Japanese hemophiliacs Yushi Chikasawa Received Received
  47-PO Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis Costello Medical Received Received
  50-PO Investigating the risk of intravenous ferric carboxymaltose (FCM)-induced hypophosphatemia in patients with inherited bleeding disorders at Sheffield Teaching Hospitals (STH). Gary Deakin Received Received
  54-PO A real world study of haemophilia treatment satisfaction, bleeds, health related quality of life as reported by patients and physicians to demonstrate gaps. Valeria Merla Received Received
  60-PO Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study Jo McCarthy Received Received
  63-PO Valoctocogene roxaparvovec estimated long-term durability of treatment effect: An extrapolation of the most recent clinical data Gillian Clague Received Received
  64-PO Number needed to scan with Point-of-care Ultrasonography for screening hemarthrosis in hemophilia patients Natalia Duque Received Received
  67-PO Unmet Needs of Patients With Haemophilia A/B With or Without Inhibitors: Real-World End-of-Study Results From the explorer6 Non-Interventional Study Giancarlo Castaman Received Received
  69-PO How to increase joint disease assessment in patient with haemophilia: from theory to practice ignazio Iasiello Received Received
  71-PO Developing Evidence-Based Guidelines for AAV Gene Therapy in Hemophilia Donna Coffin Received Received
  75-PO Subclinical Joint bleeding in Patients with Hemophilia: A Systematic Review Fahad Alabbas Received Received
  79-PO Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study Costello Medical Received Received
  80-PO Association of Bleeding Rate and ABO Blood Group with Prophylaxis in Non-Severe Hemophilia A David Schmidt Received Received
  82-PO Final analysis of the phase 1/2 trial of valoctocogene roxaparvovec for severe hemophilia A Priyanka Raheja Received Received
  83-PO Annualised Bleeding Rates in Patients with Haemophilia A or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 explorer7 Study Silvia Linari Received Received
  88-PO Real-world bleeding rates of people with severe haemophilia A on emicizumab treatment in the Netherlands with and without a history of an inhibitor Elisabeth Taal Received Received
  93-PO Long-term data of the effect of ankle joint distraction in hemophilic arthropathy Lize van Vulpen Received Received
  95-PO Joint health in women with hemophilia- reality in 2024- a survey Rosa Sonja Alesci Received Received
  96-PO TSUBASA: A prospective study evaluating association between physical activity and bleeding events, quality of life, and safety in people with haemophilia A without factor VIII inhibitors Helen Miller Received Received
  102-PO Shared Decision Making Around Emicizumab Dosing Frequency to Support Adherence Natasha Longsmith Received Received
  104-PO Real-World Effectiveness of Eptacog Beta Coagulation Factor VIIa (Recombinant) in the USA PASCALINE BELLEVILLE-BOISSAYE Received Received
  107-PO UK survey of patient perspectives of dental care when living with a bleeding disorder. Debra Morgan Received Received
  109-PO Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed Liz Southey Received Received
  110-PO Retrospective Analysis of Pregnancy and Birth Outcomes in Hemophilia Carriers: A 10-Year Review of Known and Undiagnosed Cases from Southern Italy Marta Mattana Received Received
  118-PO Acquired Hemophilia-management strategies: A single center experience Liat Waldman Radinsky Received Received
  119-PO Advocacy to improve the quality of educational initiatives for patients with rare bleeding disorders: proposed methodology Thomas Sannié Received Received
  120-PO Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study Costello Medical Received Received
  133-PO Feasibility of tests for motor skills (general fitness, proprioception and balance) in patients with hemophilia and association with pain and orthopedic joint status Katharina Holstein Received Received
  135-PO Management of pregnancy in women with inherited bleeding disorders; 10 years of experience in managing haemophilia carriers and von Willebrands disease within 2 Haemophilia comprehensive care centres within the UK Emily Millen Received Received
  139-PO Innovative tool as part of educational workshops for reporting on learning by teenagers living with hemophilia Thomas Sannié Received Received
  140-PO Are Women Welcome in Haemophilia Clinical Trials? Meaghan ODonnell Received Received
  142-PO Enhancing Global Collaboration: The Role of Data Governance in the WFH Gene Therapy Registry Mayss Naccache Received Received
  144-PO Single center experience of efanesoctocog alfa in adult and pediatric patients withhemophilia A. Kim Schafer Received Received
  148-PO Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed Liz Southey Received Received
  151-PO Deciding type of prophylaxis in previously untreated / minimally treated infants with hemophilia: Report from a pediatric center Marina Economou Received Received
  152-PO Developing a Prioritized Set of Advocacy Indicators for Enhanced Hemophilia Care in Africa Using WBDR and AGS Data Donna Coffin Received Received
  163-PO Patient Views on Transitioning from Emicizumab to Efanesoctocog Alfa Prophylaxis: Results from an Online Survey Evelien Krumb Received Received
  175-PO Real world experience with the use of Emicizumab in hemophilia A patients with and without inhibitors in Morocco :Insights from a low- and middle-income country. Nisrine Khoubila Received Received
  192-PO Management of patients with hemophilia undergoing percutaneous coronary intervention: pre and post-operative treatment Gianluca Sottilotta Received Received
  202-PO The hemorrhagic profile of hemophiliacs with inhibitors Experience of CHU Oran Cherif hosni Aicha Received Received
  208-PO Real-world quality of life data in patients with haemophilia A and haemophilic arthropathy after 1 year of emicizumab therapy Karla Rener Received Received
  215-PO Case report of Emicizumab in young patient with acquired haemophilia Emily Millen Received Received
  216-PO EXPERIENCE WITH EMICIZUMAB IN PATIENTS WITH MODERATE-SEVERE HEMOPHILIA A IN OUR CENTER Cristina Vaz Silva Received Received
  224-PO Reviewing the diagnosis of von Willebrand disease using new laboratory tests and recent consensus guidelines in paediatric patients attending the Paediatric Coagulation Centre at Childrens Health Ireland at Crumlin Beatrice Nolan Received Received
  237-PO Self-BAT and PBAC Scores in Adolescents From The General Dutch Population: Results From The Menstruation Education Calendar App. Anne de Vaan Received Received
  242-PO Increased prophylactic dosing frequency reduces bleeding in von Willebrand disease patients requiring more haemostatic coverage Gillian Patman Received Received
  243-PO Title: Health-related quality of life of French adults with von Willebrand disease: WiSH-QoL study results according to von Willebrand factor (VWF: RCo) activity levels. Marie-Hélène ANDRE-BONNET Received Received
  245-PO The Significance of von Willebrand Factor Multimer analysis in the Clinical Classification of von Willebrand Disease: A Centres Experience PANAGIOTIS CHRISTOFOROU Received Received
  247-PO Regular prophylaxis with a 1:1 von Willebrand factor/Factor VIII concentrate is effective for reducing joint and muscle bleeds in children and adults with von Willebrand disease Gillian Patman Received Received
  249-PO Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery Yaquine Mechelfekh Received Received
  250-PO von Willebrand factor (VWF:RCo) activity levels have an impact on health-related quality of life of adolescents with von Willebrand disease (VWD) and their family Marie-Hélène ANDRE-BONNET Received Received
  251-PO Efficacy and Safety of Prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate in Male and Female Patients with von Willebrand Disease Gillian Patman Received Received
  256-PO Efficacy of Prophylactic Emicizumab in Type III Von Willibrand Disease Patients: A Report of Two Cases. ohoud kashari Received Received
  260-PO Use of thalidomide for refractory bleeding in von Willebrand disease. Olga Tsiamita Received Received
  275-PO Management of pregnancy and childbirth in Glanzmann Thrombasthenia: a scoping review Karlijn Rutten Received Received
  277-PO FXI deficiency beyond bleeding- is there a higher risk for allergic diseases? Rosa Sonja Alesci Received Received
  283-PO Update on a Phase 3 Study of a Double Virus-Inactivated Human Antithrombin Concentrate During Surgery or Childbirth in Patients with Congenital Antithrombin Deficiency Sarah Baker Received Received
  292-PO Management of Glanzmann Disease: Understanding Management of Anti-Platelet Antibodies via a European Survey Mathieu Fiore Received Received
  295-PO SURGICAL PROPHYLAXIS IN PATIENTS WITH RARE COAGULATION FACTOR DEFICIENCIES: EXPERIENCE FROM A SECOND-LEVEL HOSPITAL Carmen Gil Barroso Received Received
  299-PO Successful subcutaneous infusion of plasmatic F VII - concentrate for bleeding prophylaxis Wolfgang Eberl Received Received
  305-PO Efficacy and Safety of a New Human Fibrinogen Concentrate for Treatment of Bleeding Events in Patients with Congenital Fibrinogen Deficiency Eugenio Rosado Received Received
  318-PO An Audit of the Diagnosis of Bleeding Disorder of Unknown Cause Chi-Jun Chan Received Received
  331-PO Light transmission aggregometry is not suitable for monitoring hemostatic changes after platelet transfusion in Glanzmann thrombasthenia Karlijn Rutten Received Received
  336-PO Severe FV deficiency leading To Intracranial haemorrhage Renester Fenton Received Received
  338-PO Management of acquired factor X deficiency in a patient with multiple myeloma: a case study Filomena Daniele Received Received
  352-PO Nurse Therapeutic Education Management for patients with non-acquired haemophilia treated with Emicizumab in France Celine CHENUEL Received Received
  359-PO Educational Needs of Health Care Providers regarding Women and Girls with Bleeding Disorders an online survey Gaelle Notzli Received Received
  362-PO Unmet Clinical and Psychosocial Needs in Women with Coagulopathies: Findings from a National Meeting LAURA QUINTAS Received Received
  367-PO Occupational Therapy - The Developing role of Occupational Therapy within Haemophilia ServicesHaemophilia Comprehensive Care Centre, Belfast Health & Social Care Trust Claire Forde Received Received
  370-PO Exploring unmet patient needs in haemophilia: a qualitative study on joint bleed treatment in the US Enrico Mastroianni Received Received
  373-PO Factors Associated with Health-Related Quality of Life in Obligate Carrier Women of Haemophilia Claudia Sossa Received Received
  378-PO Remote Monitoring of Physical Function in Children with Haemophilia: Reliability of Telehealth for the Six-Minute Walk, Vertical Jump, and Triple Hop Tests David Stephensen Received Received
  385-PO An examination of barriers and facilitators to physical activity and sports participation in children and adolescents with haemophilia (in Ireland). Paula Loughnane Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
04:27
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

18th Annual EAHAD Congress

 

4 - 7 February 2025 Milan
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 04/02/2042 TO 04/02/2042
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert